New drug shows promise in slowing kidney disease progression
NCT ID NCT04573920
First seen Jun 08, 2026 · Last updated Jun 08, 2026
Summary
This study tests an oral drug called atrasentan in 103 adults with kidney diseases that cause protein leakage in urine, such as IgA nephropathy and FSGS. The goal is to see if atrasentan can lower protein levels and protect kidney function over 12 to 30 weeks. Participants must already be on stable blood pressure medication. This is an early-phase trial, so results will guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Academic Medical Research Institute
Los Angeles, California, 90022, United States
-
Baylor Scott and White
Dallas, Texas, 75246, United States
-
Brookview Hills Research Assoc
Winston-Salem, North Carolina, 27103, United States
-
Colorado Kidney Care Nephrology
Denver, Colorado, 80230, United States
-
DaVita Clinical Research
Las Vegas, Nevada, 89146, United States
-
Kidney Disease Medical Group
Glendale, California, 91206, United States
-
Milwaukee Nephrologists SC
Wauwatosa, Wisconsin, 53226, United States
-
Mountain Kidney And Hyper Associa
Asheville, North Carolina, 28801, United States
-
North America Research Institute
San Dimas, California, 91773, United States
-
Northwest Louisiana Nephrology Research
Shreveport, Louisiana, 71101-4440, United States
-
Novartis Investigative Site
Gosford, New South Wales, 2250, Australia
-
Novartis Investigative Site
Herston, Queensland, 4029, Australia
-
Novartis Investigative Site
Clayton, Victoria, 3168, Australia
-
Novartis Investigative Site
Reservoir, Victoria, 3073, Australia
-
Novartis Investigative Site
St Albans, Victoria, 3021, Australia
-
Novartis Investigative Site
St Leonards, 2065, Australia
-
Novartis Investigative Site
Roma, RM, 00165, Italy
-
Novartis Investigative Site
Cheonan, Chungcheongnam-do, 330-721, South Korea
-
Novartis Investigative Site
Anyang-si, Gyeonggi-do, 14068, South Korea
-
Novartis Investigative Site
Seoul, Korea, 02841, South Korea
-
Novartis Investigative Site
Seoul, 03722, South Korea
-
Novartis Investigative Site
Seoul, 134 727, South Korea
-
Novartis Investigative Site
Port de Sagunt, Valencia, 46520, Spain
-
Novartis Investigative Site
Barcelona, 08035, Spain
-
Novartis Investigative Site
Lugo, 27004, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Majadahonda, 28222, Spain
-
Novartis Investigative Site
Sheffield, South Yorkshire, S10 2JF, United Kingdom
-
Novartis Investigative Site
London, E1 1BB, United Kingdom
-
Prolato Clinical Research Center
Houston, Texas, 77054, United States
-
Stanford U School Of Medicine
Stanford, California, 94305, United States
-
Tufts Medical Center
Boston, Massachusetts, 02111, United States
-
Uni of Minnesota Hos and Clinics
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.